Inquiry Basket
- Home
- Services
- Solutions
- Products
- Order
- Resource
- Company
* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
BOC Sciences stands at the forefront of the field of targeted protein degradation as a leading CRO. We specialize in providing comprehensive services for the design and development of PROTAC molecules targeting ERK5, offering tailored solutions to advance your research endeavors.
We offer customized design services for ERK5 PROTAC molecules tailored to your specific project requirements. Our experienced team collaborates closely with you to design PROTAC molecules with optimal binding affinity and selectivity for ERK5 degradation.
By leveraging structural insights into the interaction between ERK5 and its binding partners, such as CRBN and VHL, we can design PROTAC molecules capable of recruiting the E3 ubiquitin ligase complex to facilitate ERK5 degradation. Through iterative optimization and characterization, lead PROTAC candidates can be identified based on their ability to efficiently degrade ERK5 while maintaining favorable pharmacological properties.
Our state-of-the-art synthesis and characterization facilities enable us to efficiently synthesize and characterize ERK5 PROTAC molecules. We ensure the highest quality and purity of PROTAC compounds through rigorous analytical methods.
BOC Sciences conducts comprehensive functional evaluations to assess the degradation efficacy, kinase activity inhibition, and selectivity profiles of ERK5 PROTAC molecules. We provide valuable insights into the biological activity and performance of PROTAC compounds through thorough testing.
Characterization of ERK5-targeting PROTACs involves comprehensive evaluation of their degradation efficacy, kinase activity inhibition, and selectivity profiles. Functional assays using cellular models can assess the ability of PROTACs to induce ERK5 degradation, while biochemical assays can determine their potency in inhibiting ERK5 kinase activity. Moreover, selectivity profiling against other kinases and proteins ensures the specificity of PROTACs for ERK5, minimizing off-target effects and enhancing safety profiles.
We understand that each research project is unique, and we offer customized solutions to meet your specific objectives. Whether you require optimization of existing PROTAC designs or the development of novel molecules, we are committed to delivering tailored solutions to advance your research goals.
At BOC Sciences, confidentiality and quality assurance are paramount. We prioritize the confidentiality of your research data and intellectual property, and our commitment to quality ensures reliable and reproducible results in every project.
The extracellular signal-regulated kinase 5 (ERK5) signaling pathway plays a pivotal role in cellular physiology, particularly in processes such as cell proliferation, survival, migration, and angiogenesis. As a member of the mitogen-activated protein kinase (MAPK) family, ERK5 is implicated in various cellular responses to extracellular stimuli. Activation of the ERK5 pathway can occur through canonical mechanisms involving the MEK5-ERK5 pathway or non-canonical mechanisms, including phosphorylation by other kinases such as ERK1/2, CDK1, or CDK5. Once activated, ERK5 translocates to the nucleus, where it regulates the transcription of downstream target genes, including transcription factors like MEF2, SAP1, c-Myc, and SGK. Consequently, dysregulation of the ERK5 signaling pathway has been associated with various diseases, including cancer, making it an attractive target for therapeutic intervention.
While significant progress has been made in the development of ERK5 inhibitors, several challenges persist. One of the major concerns is the lack of selectivity exhibited by some ERK5 inhibitors, leading to off-target effects and limited efficacy. Additionally, the potential for paradoxical activation of the ERK5 pathway by certain inhibitors poses a significant risk, underscoring the need for precise targeting strategies to achieve therapeutic benefits while minimizing adverse effects.
PROTACs represent a groundbreaking approach to targeted protein degradation, offering the potential to overcome the limitations associated with traditional small molecule inhibitors. By harnessing the cellular ubiquitin-proteasome system, PROTACs induce the degradation of target proteins, thereby offering a more comprehensive and potentially safer therapeutic approach. In the context of ERK5 inhibition, PROTACs provide a promising strategy to selectively degrade ERK5 protein, offering potential advantages in terms of specificity and efficacy.
* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Please contact us with any specific requirements and we will get back to you as soon as possible.
